Albireo Pharma Past Earnings Performance
Past criteria checks 0/6
Albireo Pharma's earnings have been declining at an average annual rate of -18.1%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 49.3% per year.
Key information
-18.1%
Earnings growth rate
-3.0%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | 49.3% |
| Return on equity | -131.1% |
| Net Margin | -228.5% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Albireo Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 57 | -131 | 80 | 87 |
| 30 Jun 22 | 51 | -36 | 77 | 85 |
| 31 Mar 22 | 45 | -33 | 72 | 83 |
| 31 Dec 21 | 41 | -34 | 71 | 81 |
| 30 Sep 21 | 11 | -48 | 65 | 81 |
| 30 Jun 21 | 9 | -136 | 59 | 82 |
| 31 Mar 21 | 9 | -120 | 51 | 79 |
| 31 Dec 20 | 8 | -108 | 44 | 76 |
| 30 Sep 20 | 12 | -90 | 35 | 70 |
| 30 Jun 20 | 11 | -82 | 30 | 60 |
| 31 Mar 20 | 11 | -78 | 27 | 53 |
| 31 Dec 19 | 10 | -63 | 24 | 45 |
| 30 Sep 19 | 4 | -71 | 23 | 41 |
| 30 Jun 19 | 3 | -63 | 21 | 38 |
| 31 Mar 19 | 2 | -61 | 20 | 34 |
| 31 Dec 18 | 13 | -46 | 18 | 31 |
| 30 Sep 18 | 12 | -35 | 17 | 26 |
| 30 Jun 18 | 12 | -28 | 17 | 19 |
| 31 Mar 18 | 11 | -19 | 17 | 16 |
| 31 Dec 17 | 0 | -24 | 16 | 13 |
| 30 Sep 17 | 3 | -31 | 16 | 10 |
| 30 Jun 17 | 3 | -28 | 13 | 9 |
| 31 Mar 17 | 11 | -20 | 12 | 9 |
| 31 Dec 16 | 11 | -16 | 10 | 8 |
| 30 Sep 16 | 13 | -5 | 8 | 8 |
| 30 Jun 16 | 13 | -4 | 8 | 7 |
| 31 Mar 16 | 5 | -8 | 5 | 6 |
Quality Earnings: ALBO * is currently unprofitable.
Growing Profit Margin: ALBO * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALBO * is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.
Accelerating Growth: Unable to compare ALBO *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALBO * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).
Return on Equity
High ROE: ALBO * has a negative Return on Equity (-131.05%), as it is currently unprofitable.